Research Reference
Tesofensine
Triple monoamine reuptake inhibitor — appetite suppression (oral, trial-dosed)
Research & educational purposes only. BioMaxFit does not sell, promote, or represent peptides in any way. We are strictly educational and recommend working with your doctor on anything health-related. The information below comes from published research and documents what has been studied, not what should be done. Many of these compounds are investigational and not approved by the FDA; possession or use outside an authorized clinical trial may be illegal in your jurisdiction. This is not medical advice.
Tesofensine is an oral small-molecule triple monoamine reuptake inhibitor — not a peptide — developed for weight loss and studied in Phase 2 trials as a once-daily 0.5 mg capsule. It works by inhibiting reuptake of dopamine, serotonin, and norepinephrine, producing appetite suppression and increased energy expenditure.
Community protocols describe starting at 0.25 mg daily for 1–2 weeks to assess tolerance, then moving to 0.5 mg daily. The TIPO-1 data show the 0.5 mg dose achieving roughly 88% of the 1.0 mg weight-loss result — nearly equivalent efficacy with substantially fewer side effects.
Tesofensine is an investigational drug not approved by the FDA.
Reconstitution
No reconstitution needed — tesofensine is taken orally as a capsule. Store at room temperature. Same-time daily dosing is commonly described.
Cycling Protocol
Tesofensine's monoamine mechanism makes tolerance a real consideration. Community protocols most commonly describe 8 weeks on, 4 weeks off.
Signs of developing tolerance that community sources describe (typically weeks 4–6): appetite suppression weakening, the energy boost diminishing, return of cravings. Community sources describe cycling off rather than increasing the dose when these appear.
Alternative: 5-on/2-off weekly — 5 days on (Mon–Fri), 2 days off (weekends), continuing for 10–12 weeks before a full 4-week break. Given the ~220-hour parent-compound half-life, the 2-day break may not provide meaningful receptor recovery, and community sources describe the 8/4 cycle as more effective for managing tolerance.
Routes of Administration
Oral (only route): Swallow the capsule whole in the morning, fasted or with a light meal — absorption is not significantly affected by food, though some users report faster onset fasted. Same-time daily dosing is commonly described.
No reconstitution needed. Not an injectable.
Stacking Protocols
Tesofensine + GLP-1 Agonist
| Compound | Dose | Route | Purpose | | --- | --- | --- | --- | | Tesofensine | 0.5 mg daily | Oral | Appetite suppression via DA/NE/5-HT, energy expenditure | | Semaglutide or Tirzepatide | Per protocol | SC | Satiety via GLP-1, gastric emptying |
Completely different mechanisms — some community sources report more effective appetite control than either alone. Community sources describe keeping both at moderate doses, since combined suppression can be strong.
Side Effects & Safety
At 0.25 mg: Mild dry mouth, slight sleep difficulty if taken late, occasional headache, mild heart rate increase (2–5 bpm).
At 0.5 mg: Dry mouth (most common), insomnia (more common with afternoon or evening dosing), elevated heart rate (5–10 bpm), constipation, mild mood elevation.
At 1.0 mg (rarely reported in protocols): Significant heart rate increase (8–15+ bpm), more frequent insomnia, anxiety/jitteriness, nausea, mood swings.
Discontinuation when: Resting heart rate consistently above 100 bpm, insomnia persists beyond one week, or significant anxiety, palpitations, or blood-pressure spikes appear.
Contraindications: Cardiovascular disease, uncontrolled hypertension, history of stroke, arrhythmias, glaucoma, hyperthyroidism, seizure history.
Avoid combinations with: MAOIs (serotonin-syndrome risk), SSRIs/SNRIs (serotonergic overlap), stimulants (amphetamines, methylphenidate, modafinil), and other monoamine reuptake inhibitors (sibutramine, bupropion).
Research Basis
The landmark Phase II trial (TIPO-1, Astrup et al., 2008, PMID 18579710) tested three doses against placebo over 24 weeks with a controlled diet:
| Dose | Weight Loss | vs Placebo | | --- | --- | --- | | 0.25 mg | 6.7% | Significant | | 0.5 mg | 11.3% | Highly significant | | 1.0 mg | 12.8% | Highly significant |
The jump from 0.25 mg to 0.5 mg was substantial (nearly double), while 0.5 mg to 1.0 mg gained only 1.5 percentage points with far more side effects. This dose-response curve is why the community settled on 0.5 mg.
Sjödin et al. (2010, PMID 21414090) showed tesofensine increased energy expenditure and reduced appetite through triple monoamine reuptake inhibition — dopamine, serotonin, and norepinephrine.